← All Promis Neurosciences INC filings

Promis Neurosciences INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PMN
Promis Neurosciences INC
10-K: ProMIS Neurosciences Advances Alzheimer's Trial, Secures Funding
ProMIS Neurosciences reports significant progress in its lead Alzheimer's disease clinical trial, PMN310, and strengthens its financial position with recent capital raises.
NASDAQ
PMN
Promis Neurosciences INC
10-K: ProMIS Neurosciences Reports Continued Losses in 2024, Focuses on Advancing Alzheimer's and ALS Therapies
ProMIS Neurosciences reports ongoing losses in its 2024 10-K filing while highlighting progress in clinical trials for Alzheimer's disease and preclinical development for ALS and MSA therapies.
NASDAQ
PMN
Promis Neurosciences INC
10-K: ProMIS Neurosciences 2023 10-K Filing: Focus on Clinical Trials and Pipeline Expansion
ProMIS Neurosciences' 2023 annual report highlights progress in clinical trials for PMN310, along with continued development of its pipeline targeting neurodegenerative diseases.